Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Average Recommendation of "Reduce" by Brokerages

Key Points

• Integra LifeSciences Holdings Corporation has received an average analyst recommendation of "Reduce", with ratings of four sell, three hold, and two buy from the nine analysts covering the stock.
• The average 12-month price target for the stock is $18.63, with several analysts recently decreasing their price objectives, with Wells Fargo setting a target of $13.00.
• Despite a slight increase in Q2 earnings per share, Integra LifeSciences reported a negative net margin of 30.87% and a revenue decline of 0.6% compared to the previous year.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) have received an average rating of "Reduce" from the nine analysts that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $18.6250.

IART has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. JMP Securities decreased their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Finally, Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th.

Integra LifeSciences Price Performance

IART traded up $0.38 during midday trading on Friday, reaching $12.75. 1,189,591 shares of the company's stock were exchanged, compared to its average volume of 1,010,027. The firm has a market capitalization of $993.35 million, a price-to-earnings ratio of -1.94, a price-to-earnings-growth ratio of 0.72 and a beta of 1.16. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. Integra LifeSciences has a one year low of $11.06 and a one year high of $27.13. The business has a 50-day simple moving average of $12.59 and a two-hundred day simple moving average of $17.45.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.02. The firm had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences's revenue was down .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 EPS. As a group, research analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

A number of institutional investors have recently bought and sold shares of the company. Campbell & CO Investment Adviser LLC bought a new stake in Integra LifeSciences during the second quarter valued at $632,000. Access Investment Management LLC bought a new position in shares of Integra LifeSciences during the 2nd quarter worth about $5,348,000. AlphaQuest LLC bought a new position in shares of Integra LifeSciences during the 2nd quarter worth about $73,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock worth $38,000 after purchasing an additional 2,108 shares in the last quarter. Finally, Allianz Asset Management GmbH boosted its position in shares of Integra LifeSciences by 53.7% during the 2nd quarter. Allianz Asset Management GmbH now owns 229,904 shares of the life sciences company's stock worth $2,821,000 after purchasing an additional 80,290 shares in the last quarter. Institutional investors own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.